A report on billing codes, not a rule β but get your diagnosis documented now
HHS released a commissioned report analysing 2015β2025 insurance claims, alleging that puberty blockers for minors were billed under endocrine diagnosis codes rather than gender-dysphoria ones β around $50m under E34.9 and $11m under E30.1 for ages 13 to 17. The release states that named hospitals and clinics were referred to the Department of Justice and the HHS Office of Inspector General.
The practical consequence for a patient is attention on those codes. If you or your child take a GnRH agonist for a reason that is not gender dysphoria β precocious puberty, endometriosis, fibroids, prostate cancer β it is worth having the diagnosis documented in your own records now rather than at the point a claim is questioned. OPM told federal carriers in August 2025 not to exclude whole classes of drugs for exactly this reason.
What it does not do. It is a report and a referral, not a rule. It changes no coverage requirement, creates no new exclusion, and does not itself make any care unlawful. Nothing in it is addressed to adults.